• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics General Chronic Disease Classics

The RAVE trial: Rituximab for ANCA-associated vasculitis [Classics Series]

byAndrew Cheung, MD MBA
June 23, 2013
in General Chronic Disease Classics, The Classics
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: PD

1. Rituximab is non-inferior to cyclophosphamide in inducing remission of severe ANCA-associated vasculitis.

2. There were no significant differences between the two groups in the rate of total, serious, or non-disease-related adverse events.

Original Date of Publication: July 15, 2010

Study Rundown: The combination of cyclophosphamide and glucocorticoid has long been the standard of treatment for ANCA-associated vasculitides. The RAVE trial demonstrated that rituximab was non-inferior to cyclophosphamide in inducing remission in severe ANCA-associated vasculitis, when used alongside glucocorticoids. Moreover, there were no significant differences between the two groups in the rates of total, severe, or non-disease-related adverse events. The authors noted that their trial only included patients with severe ANCA-associated vasculitis, thereby limiting its generalizability. Others have also criticized this trial for its short follow-up and point to the paucity of data regarding long-term efficacy and safety. Rituximab subsequently received approval from the Food and Drug Administration for use in treating certain ANCA-associated vasculitides. One group has also recommended the use of rituximab, while cautioning the lack of data regarding long-term effects.

Please click to read study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does RAVE apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

In-Depth [randomized, controlled study]: The RAVE trial, published in 2010 in NEJM, was a randomized, double-blind, double-dummy, non-inferiority trial examining the efficacy of rituximab in inducing remission of severe ANCA-associated vasculitis. Patients were eligible if they had Wegner’s granulomatosis or microscopic polyangitis, positive serum assays for proteinase 3-ANCA or myeloperoxidase-ANCA and a Birmingham Vasculitis Activity Score for Wegener’s Granulomatosis (BVAS/WG) of 3 or more. Both patients with new diagnoses and relapsing disease were eligible for the trial. Eligible participants were randomized to receive either rituximab (375 mg/m2 IV weekly for 4 weeks) or cyclophosphamide (2 mg/kg, with adjustments for renal insufficiency) with a subsequent switch to azathioprine if remission was achieved between 3-6 months. Both groups were also treated with glucocorticoids (i.e., 1-3 pulses of methylprednisolone, with subsequent prednisone tapered according to symptomology). The primary endpoint was a BVAS/WG score of 0 and successful completion of prednisone taper at 6 months.

A total of 197 patients with ANCA-associated vasculitis were enrolled in the trial. Approximately 64% of patients in the rituximab group and 53% of the patients in the cyclophosphamide group reached the primary endpoint, and this treatment difference met the criterion for non-inferiority (P<0.001). The difference between the two groups, however, was not statistically significant. There were no significant differences between the groups in the rates of total, severe, or non-disease-related adverse events.

By Adrienne Cheung, Andrew Cheung, M.D.

Citation: Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/nejmoa0909905. Epub 2010 Jul 14. PMID: 20647199; PMCID: PMC3137658.

© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: PD

Tags: RAVErituximabvasculitis

Our coverage

  • Rituximab noninferior to conventional therapy in ANCA-associated vasculitis: RAVE Trial Aug 2013

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Internal medicine Classics

Previous Post

Emerging coronavirus found to spread in healthcare facilities

Next Post

New guidelines for intrapartum management of patients with mental disorders

Next Post

New guidelines for intrapartum management of patients with mental disorders

Parental smoking cessation intervention effective in pediatric practices

AAP policy statement addresses care of LGBTQ youth

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Less social media usage is associated with improved internalizing symptoms in high-risk young adults.
  • AI cardiac MRI analysis marginally outperforms clinicians in predicting all-cause mortality
  • In a phase 3 trial, tirzepatide reduced BMI versus placebo in adolescents with obesity and obesity-related complications
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.